Contract development and manufacturing organization Lonza (Basel, Switzerland) and Agilent Technologies (Santa Clara, California, USA) have agreed a collaboration deal to transform the manufacturing process for personalized cell therapies
Cell therapies are a rapidly growing and developing industry with a number of products in clinical development. Inherently complex with highly specific patient needs, cell therapies represent an uncompromising challenge to researchers because ensuring product consistency requires real-time information on critical quality attributes (CQAs) and analytics throughout the production process. Minor changes during manufacturing could potentially cause major changes in the quality and efficacy of the final product.
The deal will see Agilent integrate its analytics technologies with Lonza’s Cocoon cell manufacturing platform. The companies hope that by integrating Agilent analytical technologies both at-line and in-line within the Cocoon platform automated manufacturing workflows manufacturers will be able to ensure that in-process controls and analytics can be employed on-demand to deliver a more consistent drug product.
“There is a huge opportunity through this partnership to determine what the ideal critical quality attributes are for manufacturing the most effective cell therapy, and drive the manufacturing, optimally in real-time, to meet those criteria,” said Nicholas Ostrout, Senior Director, Business Strategy and Implementation, Personalized Medicine, at Lonza.
For more information, please visit: www.lonza.com or www.agilent.com
Inside the Laboratory: The Gionfriddo Group at the University of Buffalo
March 28th 2024In this edition of “Inside the Laboratory,” Emanuela Gionfriddo, PhD, an associate professor of chemistry at the University at Buffalo, discusses her group’s current research endeavors, including using solid-phase microextraction (SPME) coupled to liquid chromatography (LC) and gas chromatography (GC) to further understand the chemical relationship between environmental exposure and disease and elucidate micropollutants fate in the environment and biological systems.
Transferring Methods to Compact and Portable HPLC
February 14th 2024The current trend in laboratory equipment design is the miniaturization of laboratory instruments. Smaller-scale HPLC instruments offer benefits that cannot be matched by analytical-scale equipment, especially in the areas of portability, reduced fluid volumes, and reduced operating costs. Yet, the miniaturization of laboratory equipment has brought with it a unique set of challenges, including transferring methods to compact LC. Capillary LC expands the use of LC to applications not currently done using conventional LC in a wide array of application areas, including pharmaceutical, food and beverage, petrochemical, environmental, and oil and gas. Greg Ward, Axcend’s CEO wrote, “Customers want an HPLC system with a small footprint, low flow rates and green chemistry.” Join his podcast where he shares method transfer in these application areas.
Sustainable Green Solvents in Microextraction: A Review of Recent Advancements
March 27th 2024Conventional sample preparation can be time- and resource-consuming, and a green analytical methodology can be a game-changer for scientists, in addition to facilitating selective and sensitive separations.